Skip to main content
Top
Published in: Supportive Care in Cancer 6/2010

01-06-2010 | Original Article

Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function

Authors: Richard Choo, Jennifer Long, Ross Gray, Gerard Morton, Sandra Gardner, Cyril Danjoux

Published in: Supportive Care in Cancer | Issue 6/2010

Login to get access

Abstract

Purpose

The purpose of this study is to assess sexual function among patients with clinically localized prostate cancer referred for radiotherapy and to prospectively evaluate the effect of radiotherapy on sexual function, using the Brief Sexual Function Inventory (BSFI).

Materials and methods

A descriptive study, approved by the local research ethics committee, was prospectively conducted. At baseline, patients were asked to complete a self-administered BSFI, along with other questionnaires describing their clinical condition. Patients with normal erection at baseline were asked to complete a follow-up BSFI at 6, 12, and 24 months postradiotherapy. The collected data was analyzed using the SAS software.

Results

The study accrued a total of 117 eligible patients. The mean age was 66 years. Forty-two patients (35.9%) were considered to have erectile dysfunction (ED) at baseline. They were older and more likely on one or more medications affecting potency, compared with those with normal erectile function. They had a consistently lower mean score for all the five domains of BSFI and considered sexual activity less important. Of the 75 patients reporting normal erectile function at baseline, 61 completed a follow-up BSFI questionnaire. Among the 61 patients, 52 underwent radiotherapy with external beam radiotherapy or brachytherapy. Mean scores for all the BSFI domains declined after radiotherapy, suggesting that radiotherapy adversely affected not only erectile function but also other aspects of sexual function including sexual drive and ejaculation.

Conclusion

Among the patients with clinically localized prostate cancer referred for radiotherapy, sexual dysfunction was prevalent with 35.9% reporting ED at presentation. Radiotherapy adversely affected all aspects of sexual function.
Literature
3.
go back to reference Feldman HA, Goldstein I, Hatzichristou DG et al (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151:54–61PubMed Feldman HA, Goldstein I, Hatzichristou DG et al (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151:54–61PubMed
5.
go back to reference Singer PA, Tasch ES, Stocking C et al (1991) Sex or survival: trade-offs between quality and quantity of life. J Clin Oncol 9:328–334PubMed Singer PA, Tasch ES, Stocking C et al (1991) Sex or survival: trade-offs between quality and quantity of life. J Clin Oncol 9:328–334PubMed
9.
go back to reference Chen CT, Valicenti RK, Lu J et al (2001) Does hormonal therapy influence sexual function in men receiving 3D conformal radiation therapy for prostate cancer? Int J Radiat Oncol Biol Phys 50:591–599. doi:10.1016/S0360-3016(01)01504-8 PubMed Chen CT, Valicenti RK, Lu J et al (2001) Does hormonal therapy influence sexual function in men receiving 3D conformal radiation therapy for prostate cancer? Int J Radiat Oncol Biol Phys 50:591–599. doi:10.​1016/​S0360-3016(01)01504-8 PubMed
Metadata
Title
Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function
Authors
Richard Choo
Jennifer Long
Ross Gray
Gerard Morton
Sandra Gardner
Cyril Danjoux
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 6/2010
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0675-6

Other articles of this Issue 6/2010

Supportive Care in Cancer 6/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine